Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 3. Rapid correction of low vitamin D status in nursing home residents 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesNateglinide may increase high-molecular weight adiponectin in type 2 diabetic patients with hypoadiponectinemia
Diabetes Research and Clinical Practice, 11/24/08
Iwase M et al. - Nateglinide may ameliorate hypoadiponectinemia as well as postprandial hyperglycemia in patients with type 2 diabetes mellitus.
| Previous Article | Next Article |
Today in Diabetes...keeping you current
Receive free subspecialty "5-minute updates" via email
Impact of androgen deprivation therapy on cardiovascular disease and diabetes
Journal of Clinical Oncology, 06/12/09
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet - Early Online Publication, 06/09/09
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet, 06/23/09
Today in Obesity...keeping you current
Receive free subspecialty "5-minute updates" via email
Metformin for obesity in children and adolescents: a systematic review
Diabetes Care, 06/11/09
Metabolic syndrome and risk of cancer mortality in men
European Journal of Cancer, 06/15/09
Metabolic syndrome in primary aldosteronism and essential hypertension: Relationship to adiponectin gene variants
Nutrition, Metabolism & Cardiovascular Diseases, 06/05/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Denosumab update
Current Opinion in Rheumatology, 06/11/09
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)
The American Journal of Cardiology, 06/22/09
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet - Early Online Publication, 06/09/09
Sponsor
Article Search
Sponsor